Keren G, Tepper D, Butler B, Maguire W, Willens H, Miura D, Somberg J C
J Am Coll Cardiol. 1984 Oct;4(4):742-7. doi: 10.1016/s0735-1097(84)80401-5.
Lidoflazine is a calcium channel blocking agent that is effective and safe in the treatment of angina pectoris, but has been reported to be associated with sudden death when administered for the treatment of supraventricular arrhythmias. Studies were performed in dogs to determine if lidoflazine caused a rise in serum digoxin concentration that could cause arrhythmias or if it was directly arrhythmogenic. Dogs received chronic injections of digoxin and then digoxin in combination with lidoflazine. No increase in digoxin concentration was found. Dogs also underwent programmed electrical stimulation while not receiving medications and then after incremental doses of lidoflazine administered intravenously. Lidoflazine did not cause spontaneous ventricular tachycardia and did not lower the threshold of ventricular tachycardia induction. Combined administration of lidoflazine and digoxin did not facilitate arrhythmia induction. These studies do not support a digoxin-lidoflazine interaction or a direct arrhythmogenic action of lidoflazine.
利多氟嗪是一种钙通道阻滞剂，在治疗心绞痛方面有效且安全，但据报道，在用于治疗室上性心律失常时与猝死有关。在犬类身上进行了研究，以确定利多氟嗪是否会导致血清地高辛浓度升高从而引发心律失常，或者它是否直接具有致心律失常作用。犬类接受地高辛慢性注射，然后接受地高辛与利多氟嗪联合注射。未发现地高辛浓度升高。犬类在未接受药物治疗时以及静脉注射递增剂量的利多氟嗪后还接受了程控电刺激。利多氟嗪未引发自发性室性心动过速，也未降低室性心动过速诱发阈值。利多氟嗪与地高辛联合给药并未促进心律失常的诱发。这些研究不支持地高辛与利多氟嗪之间存在相互作用，也不支持利多氟嗪具有直接致心律失常作用。
